AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$AORT

GREEN ANDREW M sold $216K of AORT

GREEN ANDREW M (SVP, Regulatory and Quality) sold 8,003 shares of ARTIVION, INC. (AORT) at an average of $27.03 ($26.02–$27.26, $0.22M total) across 2 trades over 2026-09-02 to 2026-09-03.

Original reporting
SEC EDGAR · GREEN ANDREW M
Published Sep 4, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 6:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AORT
Neutral
high confidence
Mentioned
$AORT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AORTNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or personal liquidity needs not disclosed.

Relevance 4/10Novelty 4/10Timing: post‑market filing

Background

SEC Form 4 disclosures provide primary‑source insider transaction data.

Company-level read

Ticker impact

$AORTNeutralHigh confidence
Context

Form 4 filing shows SVP Andrew Green sold 8,003 shares for $216K, reducing his stake to 51,640 shares.

Expected impact

Small downward pressure, likely within normal volatility range.

Evidence & confidence

The sale amount is relatively small for a senior executive and does not represent a large ownership change.

Market effects

Sector

Minimal effect on the broader biotech sector.

Regional

Negligible impact on US markets.

Global

None

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing rather than a negative signal.

Key entities

  • Company
    Artivion, Inc.

    Biotech firm listed on NASDAQ under ticker AORT.

  • Executive
    Andrew M. Green

    Senior Vice President, Regulatory and Quality at Artivion.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AORT insider trading history →

Related articles

SEP 16
$AORTMed

Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem

Artivion Inc. (AORT) reported Q2 2026 revenue growth of 11% to $125.8M, driven by its aortic arch portfolio. However, it posted a net loss of $13.5M, reversing from a profit a year earlier. The company completed the Endospan acquisition and received FDA approval for AMDS. Despite growth, profitability declined, and guidance was reiterated without an increase.

insidermonkey.com3 min
AUG 19
$AORTMed

Why Artivion (AORT) Stock Is Trading Up Today

Artivion (AORT) shares rose 2.5% after Canaccord Genuity raised its price target to $40, citing strong Q2 revenue of $125.8M. The stock later cooled to $29.57, up 2.3%. The company's shares have been volatile, with a 26.8% drop in May after missing earnings estimates and lowering guidance. AORT is down 33.5% YTD.

financialcontent.com2 min
AUG 14
$AORTMedAI 8/10

Artivion (AORT) Q2 2026 Earnings Call Transcript

Artivion (AORT) reported Q2 2026 revenue of $125.8M, up 9% constant currency, and adjusted EBITDA of $26.4M. The company completed the Endospan acquisition and received late-June FDA PMA approval for AMDS, expecting faster account conversion. Full-year guidance was reiterated at $480M to $496M revenue and $92M to $99M adjusted EBITDA; FCF was negative $12M.

fool.com7 min
AUG 10
$AORTMed

Artivion: Q2 Earnings Snapshot

Artivion, Inc. (AORT) reported Q2 revenue of $125.8 million and a net loss of $13.5 million, or 28 cents per share, versus a profit a year earlier. Adjusted earnings were 13 cents per share. The company expects full-year revenue of $480 million to $496 million. Shares fell sharply year to date.

local3news.com3 min